 |
(Bloomberg) -- Merck & Co.’s Covid-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter the pathogen’s genetic code.
Some researchers worry the drug may create more contagious or health-threatening variations of Covid,
Mutations linked to the use of Merck’s pill, Lagevrio, have been identified in viral samples taken from dozens of patients, according to a preprint study from researchers in the US and at the Francis Crick Institute, Imperial College London and other UK institutions.
The drug-linked mutations of the virus haven’t been shown to be more immune-evasive or lethal yet, according to the study published Friday without peer review on the medRxiv website. But their very existence highlights what some scientists say are potential risks in wider use of the drug, which was recently cleared in China.
Lagevrio works by creating mutations in the Covid genome that prevent the virus from replicating in the body, reducing the chances it will cause severe illness. Some scientists had warned before it was authorized in late 2021 that by virtue of how it works, the drug could give rise to mutations that could turn out to be problematic. The preprint paper has reawakened those worries about the Merck drug.
“There’s always been this underlying concern that it could contribute to a problem generating new variants,” said Jonathan Li, a virologist at Harvard Medical School and Brigham and Women’s Hospital in Boston. “This has largely been hypothetical, but this preprint validates a lot of those concerns.”
Learn More
https://www.nature.com/articles/s41586-023-06649-6
https://www.scmp.com/news/world/article/3208800/mercks-covid-19-drug-linked-
https://www.theguardian.com/world/2023/sep/25/use-of-antiviral-molnupiravir
No comments:
Post a Comment